BioCentury | Mar 4, 2021
Management Tracks

Amazon exec Lathia joins Flagship-backed Valo as chief product officer; plus AavantiBio, CatalYm, Corcept, Vincerx, OnCusp and more

...Reithinger, who remains a partner at Forbion, one of CatalYm’s founding investors.Metabolic, oncology and psychiatric disorder company Corcept Therapeutics Inc....
BioCentury | May 3, 2019
Finance

Earnings on deck

...Pre $0.43 $0.67 -36% Ono Pharmaceutical Co. Ltd. (Tokyo:4528) (B) 5/9 During NA ¥17.26 NA Corcept Therapeutics Inc....
BioCentury | Feb 22, 2019
Finance

Earnings on deck

...week. (A) Six-month EPS Company Date Pre/post mkt 4Q18 EPS est 4Q17 EPS Expected chg Corcept Therapeutics Inc....
BioCentury | Nov 19, 2018
Company News

Management tracks: Brickell, Genevant

...2013-14. Tocagen has initiated a search to find a permanent replacement. Metabolic and cancer company Corcept Therapeutics Inc....
BioCentury | Apr 11, 2017
Distillery Therapeutics

Infectious disease

...inhibitors in models of other post-stroke bacterial infections. Generic mifepristone is marketed as an abortifacient. Corcept Therapeutics Inc....
BioCentury | May 16, 2016
Clinical News

CORT125134: Phase I/II started

...dose-expansion phase, which will test the combination in 20-patient cohorts in >=1 solid tumor types. Corcept Therapeutics Inc....
BioCentury | Dec 21, 2015
Clinical News

Mifepristone: Additional Phase I/II data

...Cancer Symposium. Corcept has previously reported interim data from the trial (see BioCentury, June 29). Corcept Therapeutics Inc....
BioCentury | Sep 30, 2015
Company News

Management tracks

...head of U.S. medical for oncology at Bristol-Myers Squibb Co. (NYSE:BMY). Metabolic and cancer company Corcept Therapeutics Inc....
BioCentury | Jul 30, 2015
Distillery Therapeutics

Therapeutics: Glucocorticoid receptor (GCCR)

...of the neurobiological changes produced by mifepristone that are responsible for the decreased alcohol intake. Corcept Therapeutics Inc....
BioCentury | Jun 29, 2015
Clinical News

Mifepristone: Interim Phase I/II data

...2 Halaven. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Corcept...
...to start a Phase III trial of mifepristone to treat breast cancer early next year. Corcept Therapeutics Inc....
Items per page:
1 - 10 of 197
BioCentury | Mar 4, 2021
Management Tracks

Amazon exec Lathia joins Flagship-backed Valo as chief product officer; plus AavantiBio, CatalYm, Corcept, Vincerx, OnCusp and more

...Reithinger, who remains a partner at Forbion, one of CatalYm’s founding investors.Metabolic, oncology and psychiatric disorder company Corcept Therapeutics Inc....
BioCentury | May 3, 2019
Finance

Earnings on deck

...Pre $0.43 $0.67 -36% Ono Pharmaceutical Co. Ltd. (Tokyo:4528) (B) 5/9 During NA ¥17.26 NA Corcept Therapeutics Inc....
BioCentury | Feb 22, 2019
Finance

Earnings on deck

...week. (A) Six-month EPS Company Date Pre/post mkt 4Q18 EPS est 4Q17 EPS Expected chg Corcept Therapeutics Inc....
BioCentury | Nov 19, 2018
Company News

Management tracks: Brickell, Genevant

...2013-14. Tocagen has initiated a search to find a permanent replacement. Metabolic and cancer company Corcept Therapeutics Inc....
BioCentury | Apr 11, 2017
Distillery Therapeutics

Infectious disease

...inhibitors in models of other post-stroke bacterial infections. Generic mifepristone is marketed as an abortifacient. Corcept Therapeutics Inc....
BioCentury | May 16, 2016
Clinical News

CORT125134: Phase I/II started

...dose-expansion phase, which will test the combination in 20-patient cohorts in >=1 solid tumor types. Corcept Therapeutics Inc....
BioCentury | Dec 21, 2015
Clinical News

Mifepristone: Additional Phase I/II data

...Cancer Symposium. Corcept has previously reported interim data from the trial (see BioCentury, June 29). Corcept Therapeutics Inc....
BioCentury | Sep 30, 2015
Company News

Management tracks

...head of U.S. medical for oncology at Bristol-Myers Squibb Co. (NYSE:BMY). Metabolic and cancer company Corcept Therapeutics Inc....
BioCentury | Jul 30, 2015
Distillery Therapeutics

Therapeutics: Glucocorticoid receptor (GCCR)

...of the neurobiological changes produced by mifepristone that are responsible for the decreased alcohol intake. Corcept Therapeutics Inc....
BioCentury | Jun 29, 2015
Clinical News

Mifepristone: Interim Phase I/II data

...2 Halaven. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Corcept...
...to start a Phase III trial of mifepristone to treat breast cancer early next year. Corcept Therapeutics Inc....
Items per page:
1 - 10 of 197